Price History
Feb 9, 2026 — May 17, 2026Investment Snapshot
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 4.8% — below-average profitability
- Revenue declining 100% annually
vTv Therapeutics Inc. - Class A Common Stock (VTVT) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
vTv Therapeutics Inc. - Class A Common Stock — Fundamental Analysis Summary
On financial health, VTVT shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 4.8% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.41.
StockPik's composite Value Score for VTVT is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VTVT shows revenue declining at 100% year-over-year, with earnings declining at 46%.